by Truveta Staff | Jan 10, 2023 | Technology
The key to any disease study is rich data. We recently met with the CEO of a biotech company that specializes in the development of immunotherapies. He and his team had tried to recruit patients for a series of clinical trials related to several rare disease...
by Terry Myerson | Nov 2, 2022 | News
In just over two years — with amazing teamwork across Truveta and our 25 health system members, and strategic partnerships with customers like Pfizer and Boston Scientific — it is so exciting to announce the availability of Truveta Studio. It is amazing...
